Impact of prior treatment on CAR T-cell outcome in adult ALL.
作者信息
Marks David I, Castleton Anna Z
机构信息
Department of Haematology, Bristol Haematology and Oncology Centre, Bristol, United Kingdom.
Department of Haematology, Christie Hospital Manchester, Manchester, United Kingdom.
出版信息
Blood Adv. 2024 Dec 10;8(23):6137-6138. doi: 10.1182/bloodadvances.2024014237.
Abstract
摘要
相似文献
1
Impact of prior treatment on CAR T-cell outcome in adult ALL.既往治疗对成人急性淋巴细胞白血病中嵌合抗原受体T细胞治疗结果的影响。
Blood Adv. 2024 Dec 10;8(23):6137-6138. doi: 10.1182/bloodadvances.2024014237.
2
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.嵌合抗原受体 T 细胞疗法对 CD19 弱表达 B 淋巴细胞白血病有效，但会受到先前blinatumomab 治疗的影响。
Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.
3
Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival.营养不良和恶病质与较差的 CAR T 细胞治疗结果相关，包括生存率。
Clin Nutr ESPEN. 2024 Aug;62:206-215. doi: 10.1016/j.clnesp.2024.05.020. Epub 2024 May 28.
4
Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.比较非霍奇金淋巴瘤患者接受 CD19 CAR T 细胞治疗时采用的 2 天与 3 天流感样细胞减少方案。
Front Immunol. 2024 Jun 14;15:1403145. doi: 10.3389/fimmu.2024.1403145. eCollection 2024.
5
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.异基因造血干细胞移植对复发/难治性多发性骨髓瘤嵌合抗原受体（CAR）T 细胞治疗的影响。
Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):e277-e282. doi: 10.1016/j.clml.2024.05.006. Epub 2024 May 4.
6
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.既往CAR T细胞疗法对复发或难治性B细胞淋巴瘤患者中mosunetuzumab疗效的影响。
Blood Adv. 2025 Feb 25;9(4):696-703. doi: 10.1182/bloodadvances.2024013640.
7
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.CD19 靶向 CAR-T 疗法与 BEAM 化疗对成人淋巴瘤患者的营养影响。
J Hum Nutr Diet. 2023 Oct;36(5):2099-2107. doi: 10.1111/jhn.13210. Epub 2023 Jul 25.
8
Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting.真实世界环境中靶向 CD19 的嵌合抗原受体 T 细胞（axicabtagene ciloleucel）治疗侵袭性 B 细胞淋巴瘤的体内扩增和治疗结局。
Blood Adv. 2021 Jun 8;5(11):2523-2527. doi: 10.1182/bloodadvances.2020003959.
9
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.弥漫性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞（CAR T）治疗及时给药障碍的真实世界分析。
Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11.
10
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.既往塞利尼索暴露对复发/难治性多发性骨髓瘤嵌合抗原受体T细胞治疗结局的影响：一项探索性分析。
J Clin Med. 2025 Feb 16;14(4):1316. doi: 10.3390/jcm14041316.
引用本文的文献
1
The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment.嵌合抗原受体T细胞疗法与急性淋巴细胞白血病治疗中神经并发症之间的斗争
Curr Issues Mol Biol. 2025 May 21;47(5):381. doi: 10.3390/cimb47050381.
2
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab.CAR-T细胞疗法在先前接受blinatumomab治疗的B-ALL患者中的疗效和安全性。
Blood Cancer J. 2025 Feb 5;15(1):11. doi: 10.1038/s41408-025-01217-9.
本文引用的文献
1
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.既往使用奥英妥珠单抗治疗对B细胞急性淋巴细胞白血病成人患者布雷西尤单抗自体细胞治疗结果的影响。
Blood Adv. 2024 Dec 10;8(23):6139-6147. doi: 10.1182/bloodadvances.2024013747.
2
CAR T-Cells and Safety Signals: ITT Episode 29.嵌合抗原受体T细胞与安全信号：ITT第29集。
N Engl J Med. 2024 Apr 25;390(16):e39. doi: 10.1056/NEJMp2400701.
3
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.采用严格的事件定义，通过国家准入计划，评估接受 tisagenlecleucel 治疗的 r/r ALL 儿童和青少年的意向治疗结局。
Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2.
4
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.ZUMA-3 研究中，既往治疗和随后的移植对复发/难治性 B 细胞急性淋巴细胞白血病成人患者接受 brexucabtagene autoleucel 治疗结局的影响。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007118.
5
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.对复发/难治性B细胞急性淋巴细胞白血病成人患者的抗原靶向抗体和细胞疗法进行测序。
Am J Hematol. 2023 Apr;98(4):666-680. doi: 10.1002/ajh.26853. Epub 2023 Feb 6.
6
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.依妥珠单抗奥滨尤妥珠单抗对比既往治疗复发或难治性急性淋巴细胞白血病：来自随机、3 期 INO-VATE 研究的最终报告和长期生存随访。
Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.
7
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
Zotero 插件